Recludix Pharma to Present at Two Investor Conferences in February

SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging targets for inflammatory disease and cancer, today announced that Nancy Whiting, Pharm.D., chief executive officer of Recludix, will present at two investor conferences in February.

• Oppenheimer 34^th Annual Healthcare Life Sciences Conference taking place virtually
  • Presentation on Tuesday, February 13, 2024 from 11:20 – 11:50 a.m. ET
• Evercore ISI 2024 Emerging Biotech Conference taking place virtually
  • Fireside chat on Wednesday, February 28, 2024 from 3:25 – 3:55 p.m. ET

To access available live and archived webcasts, visit the News & Events page of the company’s website at https://recludixpharma.com/news-events. The archived webcasts will be available for 30 days following the presentation.

About Recludix
Recludix is a leader in developing platform approaches to discover potent and selective inhibitors of challenging protein targets. The company’s management team includes industry veterans with a track record of success, including former leaders and founding scientific team members of Seagen and Blueprint Medicines. Recludix has developed a unique drug discovery platform that integrates custom generated DNA-encoded libraries, massively parallel determination of structure activity relationships, and a proprietary screening tool to ensure selectivity. The company is employing this approach first in the development of SH2 domain inhibitors. Recludix’s most advanced programs are focused on STAT (signal transducer and activator of transcription) proteins where abnormal activation is found in inflammatory diseases, such as rheumatoid arthritis, asthma, atopic dermatitis, and inflammatory bowel disease, as well as numerous cancer types, such as multiple leukemias and lymphomas. The company has a strategic partnership with Sanofi for the development and commercialization of a STAT6 inhibitor. Recludix is also advancing STAT3 inhibitors for Th17-mediated I&I diseases and oncology indications, as well as additional programs. For more information, please visit the company’s website at https://recludixpharma.com.

Recludix Contacts:
Alexandra Santos
[email protected]

Aljanae Reynolds
[email protected]

You May Also Be Interested In

• How Can Everyday People Participate in the AI Infrastructure Boom? 51AIpower Explains the AI Token Economy
• Anne Therese Cape Coral Practice Addresses Sun Damage and Stubborn Fat
• Zcash Price Prediction: ZEC More Than Doubles From Late-August Levels as Remittix Locks In Its Launch Date